肺动脉高压伴低于阈值肺血管阻力的患者特征与结局
该研究基于澳大利亚和新西兰肺动脉高压登记系统,纳入2004年至2017年符合平均肺动脉压≥25 mmHg、肺动脉楔压≤15 mmHg且肺血管阻力<3 Wood单位的82例患者。患者接受内皮素受体拮抗剂或磷酸二酯酶5抑制剂单药治疗,首次复查时6分钟步行距离增加46米,35%患者NYHA功能分级改善;中位随访65个月,22.0%患者死亡,估计1年和5年生存率分别为98%和84%。
要点
- 肺血管阻力<3 Wood单位的毛细血管前肺动脉高压患者仍存在不良结局。
- 此类患者对肺动脉高压靶向治疗有反应,6分钟步行距离和功能分级改善。
- 需要随机试验进一步研究该人群的治疗策略。
核心结论
- 肺血管阻力低于当前定义阈值的毛细血管前肺动脉高压患者仍具有不良结局,且对肺动脉高压治疗有反应,但需随机试验进一步验证。
主要发现
- 患者平均年龄63±11岁,67例女性;病因包括特发性疾病39例、结缔组织病42例、HIV感染1例。
- 基线平均肺动脉压27 mmHg(IQR 25-30),肺动脉楔压13 mmHg(IQR 11-14),肺血管阻力2.2 Wood单位(IQR 1.9-2.7)。
- 基线6分钟步行距离352米(IQR 280-416),77%患者为NYHA功能分级3或4级。
- 所有患者初始接受内皮素受体拮抗剂(66例)或磷酸二酯酶5抑制剂(16例)单药治疗;首次复查时6分钟步行距离增加46米(IQR 7-96),35%患者NYHA功能分级改善。
- 中位随访65个月(IQR 32-101),18例(22.0%)死亡,估计1年和5年生存率分别为98%和84%;18例死亡中6例(33.3%,占总数7%)归因于肺动脉高压。
关键数值与推荐
- 肺动脉高压血流动力学定义中肺血管阻力>3 Wood单位为标准,但该 cutoff 值保守且任意。
临床怎么用
- 对于平均肺动脉压≥25 mmHg、肺动脉楔压≤15 mmHg且肺血管阻力<3 Wood单位的毛细血管前肺动脉高压患者,应认识到其仍可能存在不良结局。
- 此类患者可考虑肺动脉高压靶向治疗,但需进一步随机试验证据支持。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary vascular resistance (PVR) >3 Wood units is a criterion of the haemodynamic definition of pulmonary arterial hypertension (PAH). However, this cut-off is conservative and arbitrarily defined. Data is lacking on the natural history, response to therapy and survival of patients diagnosed with precapillary pulmonary hypertension (PH) with mild or borderline elevation of PVR.In Australia, PAH therapy could be prescribed solely on mean pulmonary arterial pressure (PAP) and pulmonary arterial wedge pressure (PAWP) criteria. Using the Australian and New Zealand Pulmonary Hypertension Registry, we aimed to study a population diagnosed with PAH between January 2004 and December 2017 with the pre-defined haemodynamic characteristics of mean PAP ≥25 mmHg, PAWP ≤15 mmHg and PVR <3 Wood units.Eighty-two patients met the pre-defined haemodynamic inclusion criteria (mean age 63±11 years; 67 females). Underlying aetiologies included idiopathic disease (n=39), connective tissue disease (CTD; n=42) and HIV infection (n=1). At diagnosis, mean PAP was 27 mmHg (interquartile range (IQR) 25-30 mmHg), PAWP 13 mmHg (IQR 11-14 mmHg) and PVR 2.2 Wood units (IQR 1.9-2.7 Wood units). Baseline 6-min walk distance (6MWD) was 352 m (IQR 280-416 m) and 77% of subjects were in New York Heart Association (NYHA) functional class 3 or 4. All patients were commenced on initial monotherapy with an endothelin receptor antagonist (ERA; n=66) or phosphodiesterase type-5 inhibitor (PDE5i; n=16). At first re-evaluation, 6MWD increased by 46 m (IQR 7-96 m) and 35% of subjects demonstrated improvement in NYHA functional class. After a median follow-up of 65 months (IQR 32-101 months), 18 out of 82 subjects (22.0%) had died, with estimated 1-year and 5-year survival rates of 98% and 84%, respectively. Death attributed to PAH occurred in six out of these 18 patients (33.3%, 7% of total cohort).Patients with precapillary PH and "borderline" PVR falling outside the current definition have adverse outcomes. Such patients appear to respond to PAH therapy; however, this requires further study in randomised trials.
引用
- Ratwatte S, Anderson J, Strange G, et al. Pulmonary arterial hypertension with below threshold pulmonary vascular resistance. Eur Respir J. 2020. PMID: 32341105. doi:10.1183/13993003.01654-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。